
## Driving Towards A Sustainable Future





#### **Contents**

CORPORATE OVERVIEW

- 02 About us
- 06 Performance highlights
- 08 Expanding horizons
- 10 Letter from the Chairman and Managing Director
- 12 Profile of the Board of Directors
- 14 Management team

STATUTORY REPORTS

- **16** Management Discussion and Analysis
- 28 Board's Report
- **59** Corporate Governance Report
- 79 Business Responsibility Report

FINANCIAL STATEMENTS

86 Standalone Financial Statements135 Consolidated Financial Statements

185 Notice



Our vision



TO BE THE GLOBAL LEADER
IN PHARMACEUTICAL
MANUFACTURING BY
PROCESS INNOVATION
AND UNPARALLELED
EFFICIENCIES.

WE ARE A VERTICALLY INTEGRATED PHARMACEUTICAL COMPANY, MANUFACTURING ACTIVE PHARMACEUTICAL INGREDIENTS (APIS), PHARMACEUTICAL FORMULATION INTERMEDIARIES (PFIS) AND FINISHED DOSAGES (FDS).

₹14,353 MN

REVENUE FROM OPERATION up 4% from 2015-16

₹3,088 MN

EBIDTA up 10% from 2015-16

₹1,645 MN

NET PROFIT up 34% from 2015-16

₹1,934 MN

NET CASH FLOW FROM OPERATING ACTIVITIES

₹7.5

EARNINGS PER SHARE (BASIC) up 25% from 2015-16

₹9,036 MN

NETWORTH up 37% from March 31, 2016

₹9,837 MN

GROSS BLOCK up 20% from March 31, 2016


₹31,755 мм

MARKET CAPITALISATION As on March 31, 2017 At Granules, our fundamental philosophy has always been a relentless pursuit to grow, year after year. We draw our growth strategies based on our fundamental strengths in vertical integration, operational efficiencies, regulatory compliances, supply security and customer centricity.

We are committed to drive and align our current as well as newer business avenues around our core philosophy. This synergy will help us create an entity that would generate sustainable value for our stakeholders.

So what are our plans for the year ahead?

To successfully drive all business verticals towards its strategic objective of building a self sustainable, future-ready and growth oriented organisation.



The cover design represents the relentless pursuit towards excellence by Granules India Limited. Our journey towards a sustainable future now strategically aligns with achieving growth in our distinguished business verticals. With a defined blue print for each businesses, we are confident of reaching our set milestones.

## **CORE BUSINESS**











# **EMERGING BUSINESS**





**CRAMS BUSINESS** 





### About us

#### MANUFACTURING FACILITIES

API	PFI	FD
Bonthapally, Telangana	Gagillapur, Telangana	Gagillapur, Telangana
Jeedimetla, Telangana	Jeedimetla, Telangana	Virginia, USA
Jingmen, China (Biocause JV)		
Visakhapatnam, Andhra Pradesh		
Visakhapatnam SEZ (Omnichem JV - CRAMs), Andhra Pradesh		
Bonthapally, Telangana (API Intermediaries)		



2,300 +

NUMBER OF EMPLOYEES AS ON MARCH 31, 2017

250 +

**CUSTOMER BASE** 

**BROAD PORTFOLIO OF PRODUCTS** 

- Active Pharmaceutical Ingredients (APIs)
- Pharmaceutical Formulation Intermediaries (PFIs)
- Finished Dosages (FDs)


60 +


**COUNTRIES OF PRESENCE** 




FD PFI API

#### CONSOLIDATED REVENUE FROM OPERATIONS BY VERTICALS





#### CONSOLIDATED REVENUE FROM OPERATIONS BY MOLECULES






## Performance highlights

Financials as per Ind AS Financials as per I-Gaap

#### Revenue from operations ₹ in million


Revenue from operations includes total income from various business operations covering both domestic and international sales. Revenue is a key measure of how we have delivered on our strategies to grow business.



#### **EBIDTA**


₹ in million

EBIDTA is a measure of the profit generated by the business, excluding interest, depreciation, amortisation and tax. EBIDTA is a key measure of profitability.




#### Profit after tax

Profit after tax is an important financial matrix as it tells the investors the true profitability earned by company, post the taxes paid to the exchequer.



#### Earnings per share


EPS is the profit after tax for the year, divided by the weighted average number of ordinary shares. Basic EPS provides a measure of shareholder return that is comparable over time.



#### Net Worth


₹ in million

It reflects the overall financial strength of the company. A positive net worth showcases the company's stability in the long-run. The increased networth is a testimony to the stable earnings over a period of time.




#### **Debt Equity**

It reflects the long-term solvency position of the Company. It indicates how much debts a Company is using to finance its assets.



#### Market Capitalisation\*

The total market value of company based on its current share price on stock exchange and the total number of shares. It reflects the size of the Company.




<sup>\*</sup> Figures as on last trading day of each financial year


#### **Gross Block**

₹ in million

It is defined as total of all assets belonging to the company, valued at their cost of acquisition. This indicates the strengthening of the asset base of the Company.



# Expanding horizons



•

#### Consolidated revenue from operation as per geography

